spacer
home > > autumn 2008 > the bpo boom
PUBLICATIONS


The BPO Boom

Thereís nothing like a darkening economic climate and rising competitive pressures to focus a businessí priorities, and few industries are being spared this experience at the moment. Like their counterparts in other commercial sectors, pharmaceutical organisations are being forced to re-examine their core and non-core activities in order to determine where new efficiencies can be found, and to drive greater productivity and competitive agility into their operations. This is leading to a surge of interest in the outsourcing of non-core activities, as pharma organisations attempt to sharpen their practices and reduce time to market.

Fortunately, as these organisations are discovering, there has been an increase in the availability and scope of managed services being offered by external specialists, which now include partial or complete outsourcing of regulatory submission operations.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Adam Sherlock is ISIís Managing Director/Vice President Europe. During a career that spans some 20 years in the IT industry, Adam has served in senior director roles in a number of life sciences-focused organisations, including IQ Consultancy, the Synapse Partnership and medical communications agency, Gardner Caldwell. Adam was awarded his honours degree in Applied Microbiology from Liverpool University.
spacer
Adam Sherlock
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement